Cusumano AM

Idioma: Español
Referencias bibliográficas: 29
Paginas: 139-146
Archivo PDF: 109.56 Kb.

FRAGMENTO

En el momento actual, se asiste en el mundo a una verdadera epidemia de las así llamadas “enfermedades crónicas no comunicables”: diabetes, hipertensión arterial, enfermedad cardiovascular, enfermedad renal crónica. Estas causarían actualmente el 60% de las muertes en el mundo, y alrededor del 47% de los gastos en salud. Se estima que serán la principal causa de muerte y discapacidad para el 2020, y la mayor carga provocada por estas enfermedades se producirá sobre los países menos desarrollados. Son, por otro lado, patologías que acompañan al envejecimiento de la población, y es bueno recordar aquí que la expectativa de vida en Latinoamérica (LA) ha aumentado de 70.5 años en el 2001 a 75.7 años en el 2006, es decir, es una población que envejece.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Yach D, Hawkes C, Gould L, Hofman K. The Global Burden of Chronic Diseases. Overcoming Impediments to Prevention and Control. JAMA, 2004; 291, 2616-2622, www.jama.com. Accessed on May 8, 2007

2. World development Indicator database, august 2003, www.worldbank.org/data. Acceso enro 15, 2005.

3. Health situation in the Americas. Basic Indicators 2006. Pan American Health Organization, available on http://www.paho.org/english/dd/ais/BI-brochure-2006.pdf, Acceso mayo 10, 2006

4. Cusumano A. Conferencia: SLANH REGISTRY 2006, presentada al Simposium Post World Congress of Nephrology 2007, Renal Disease in Minority Populations and Developing Nations. Datos aún no publicados. Rio de Janeiro, Brasil, 25-27 de abril de 2007

5. United States Renal Data System (USRDS) 2006; http://www.usrds.org/2006/ref/A_incidence_06.pdf, acceso 8 de mayo 2007.

6. Informe de situación de diálisis y trasplante 2005. http://www.senefro.org/modules, acceso 8 de mayo 2007

7. The current state of chronic dialysis treatment in Japan (as of December 31, 2000). Ther Apher Dial. 2003;7:3-35.

8. Jones C, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32; 992-999.

9. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 39:S46-S75, 2002 (suppl 1).

10. Coresh J, Astor B, Greene T. Eknoyan G, Levey A. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1-12.

11. Centers for Disease Control and Prevention (CDC). Prevalence of chronic kidney disease and associated risk factors--United States, 1999-2004. MMWR March 2, 2007; 56:161-165.

12. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, Dekker FW. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ. 2006 Nov 18; 333: 1047.

13. Presentación de resultados preliminares del Estudio Epirce. Conferencia en el V Congreso Iberoamericano de Nefrologia, Madrid, 18-21 octubre 2006.

14. Encuesta Nacional de Salud Chile 2003, http://www.minsal.cl/ici/destacados/Folleto%20FINAL.pdf, acceso 9 de mayo del 2007.

15. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16: 489-95.

16. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hopitalization. N Eng J Med 2004: 351: 1296-1305.

17. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). http://www.nhlbi.nih.gov/guidelines/hypertension/ Acceso mayo 10, 2007.

18. Segura J, Campo C, Roldán C, Christiansen H, Vigil L, García-Robles R et al. Hypertensive Renal Damage in Metabolic Syndrome Is Associated with Glucose Metabolism Disturbances. J Am Soc Nephrol 2004; 15 (Supp1): S37-42.

19. Chen J, Muntner P, Hamm L, Fonseca V, Batuman V, Whelton P, He J. Insulin Resistance and Risk of Chronic Kidney Disease in Nondiabetic US Adults. J Am Soc Nephrol 2003; 14:46-477,

20. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.

21. The human, social and economic impact of diabetes. http://www.idff.org/home/index.cfm?unode=3B9691D3-C026-2FD3-87B7FA0B63432BA3

22. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes. 1995;44:1303-1309;

23. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S for the HOPE Investigators. Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial. Ann Int Med 2001; 134: 629-636.

24. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. The Diabetes Control and Complications Trial Research Group. N Eng J Med 1993; 329: 977.986.

25. Ruggenenti P, Fassi A, Parvanova Ilieva A, Bruno S, Petrov Iliev I, Brusegan V et al. Investigators. Preventing Microalbuminuria in Type 2 Diabetes. N Eng J Med 2004;351:1941-51.

26. De Zeeuw D, Remuzzi G, Parvin H, Keane W, Zhang Z, SHAHINFAR S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 2004; 65:2309-2320

27. Sustained Effect of Intensive Treatment of Type 1 Diabetes Mellitus on Development and Progression of Diabetic Nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. JAMA 2003; 290:2159-2167.

28. Barnett A, Bain S, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin- Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy. N Eng J Med 2004; 351, 1952-1961.

29. Remuzzi G, Ruggenenti P, Perna A, Dimitrov B, de Zeeuw D, Hille D et al. Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results. J Am Soc Nephrol 2004;15: 3117-3125.